News

The company has raised the funding from new and existing investors at a pre-money valuation of $2bn in the financing round of the AI pharmaceutical sector. From 2013, BenevolentAI

The approval is based on results from the Phase III FLAURA trial, which were presented at the European Society of Medical Oncology 2017 Congress. AstraZeneca oncology business unit

The collaboration brings together Sandoz expertise in launching and commercializing treatments with Pear's leading experience in digital therapeutics design and implementation. Sandoz and Pear will work together to

The German pharma major, which has been looking at various options for the consumer health business since last September, will use the sale proceeds mainly to reduce its

Hemlibra is a bispecific factor IXa- and factor X-directed antibody. It is said to be a prophylactic (preventative) treatment that can be administered by an injection of a

Catabasis is prioritizing this program to deliver against its goal of bringing a life changing therapy to those affected by Duchenne. Catabasis CEO Jill Milne said: “This decision

The company's five-year commitment to the fight against malaria was announced in conjunction with the 7th Multilateral Initiative on Malaria Conference and the Malaria Summit of the Commonwealth

Sanofi, which had fully acquired Zentiva in a deal worth about €1.8bn in 2009, is looking to sell it after considering the European generics business to be non-core.

Unigreg owns the rights to Forceval, a micro-nutrient supplement used in pregnancy, in China and some nearby territories. Alliance will continue to market the Forceval brand in the